Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 29.28% is 360% above its 5-year average of -11.28%, near the high end of its 5-year range (-93.71%–40.22%).
As of the fiscal period ended Tuesday, June 30, 2026. 4.10% below its 12-month average of 30.53%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 29.28%.
RETURN ON EQUITY (ROE)
29.28%
RETURN ON EQUITY (ROE) AVG TTM
30.53%
RETURN ON EQUITY (ROE) AVG 3Y
10.66%
RETURN ON EQUITY (ROE) AVG 5Y
-11.28%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-4.10%
CURRENT VS 3Y AVG
+174.82%
CURRENT VS 5Y AVG
+359.52%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
+125.08%
vs the sector median at left
TransMedics Group, Inc.
Market Cap
$2.99B
Return on Equity (ROE)
29.28%
TTM Avg
30.53%
3Y Avg
10.66%
5Y Avg
-11.28%
Market Cap
$1.91B
Return on Equity (ROE)
-40.41%
TTM Avg
-45.75%
3Y Avg
-30.11%
5Y Avg
-18.95%
Market Cap
$1.14B
Return on Equity (ROE)
-13.54%
TTM Avg
-40.81%
3Y Avg
-170.75%
5Y Avg
-114.78%
Market Cap
$4.88B
Return on Equity (ROE)
18.24%
TTM Avg
20.62%
3Y Avg
17.32%
5Y Avg
27.02%
Market Cap
$5.10B
Return on Equity (ROE)
8.67%
TTM Avg
8.42%
3Y Avg
7.80%
5Y Avg
5.80%
Market Cap
$463.35M
Return on Equity (ROE)
89.43%
TTM Avg
81.07%
3Y Avg
67.39%
5Y Avg
61.90%
Market Cap
$5.59B
Return on Equity (ROE)
-161.00%
TTM Avg
-110.38%
3Y Avg
-86.51%
5Y Avg
-75.97%
Market Cap
$376.61M
Return on Equity (ROE)
-28.18%
TTM Avg
-0.06%
3Y Avg
10.58%
5Y Avg
10.58%
Market Cap
$45.05M
Return on Equity (ROE)
N/A
TTM Avg
-285.38%
3Y Avg
-206.98%
5Y Avg
-151.57%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TransMedics Group, Inc. (TMDX) | $2.99B | 29.28% | 30.53% | 10.66% | -11.28% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.91B | -40.41% | -45.75% | -30.11% | -18.95% |
| Teladoc Health, Inc. (TDOC)vs › | $1.14B | -13.54% | -40.81% | -170.75% | -114.78% |
| Doximity, Inc. (DOCS)vs › | $4.88B | 18.24% | 20.62% | 17.32% | 27.02% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.10B | 8.67% | 8.42% | 7.80% | 5.80% |
| NRC Health (NRC)vs › | $463.35M | 89.43% | 81.07% | 67.39% | 61.90% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.59B | -161.00% | -110.38% | -86.51% | -75.97% |
| Shoulder Innovations, Inc. (SI)vs › | $376.61M | -28.18% | -0.06% | 10.58% | 10.58% |
| PDS Biotechnology Corporation (PDSB)vs › | $45.05M | N/A | -285.38% | -206.98% | -151.57% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.24B | -43.83% | 25.09% | 5.57% | 0.40% |
ROE
29.3%
ROA
10.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 29.28% |
| 2026-03-31 | 34.80% |
| 2025-12-31 | 40.22% |
| 2025-09-30 | 25.83% |
| 2025-06-30 | 22.53% |
| 2025-03-31 | 18.38% |
| 2024-12-31 | 15.51% |
| 2024-09-30 | 15.55% |
| 2024-06-30 | 1.58% |
| 2024-03-31 | -6.39% |
| 2023-12-31 | -18.24% |
| 2023-09-30 | -28.29% |
| 2023-06-30 | -12.25% |
| 2023-03-31 | -14.69% |
| 2022-12-31 | -19.34% |
| 2022-09-30 | -22.45% |
| 2022-06-30 | -93.71% |
| 2022-03-31 | -78.22% |
| 2021-12-31 | -65.16% |
| 2021-09-30 | -48.20% |
| 2021-06-30 | -33.70% |
| 2021-03-31 | -28.48% |
| 2020-12-31 | -27.67% |
| 2020-09-30 | -28.86% |
| 2020-06-30 | -30.60% |
| 2020-03-31 | -76.05% |
| 2019-12-31 | -61.39% |
| 2019-09-28 | -50.42% |
| 2019-06-29 | -40.51% |
| 2018-09-30 | -799.42% |
| 2018-06-30 | -274.65% |
| 2018-03-31 | -110.75% |
| 2017-12-30 | -115.07% |
